tiprankstipranks
Upstream Bio, Inc. (UPB)
NASDAQ:UPB
US Market
UPB
Upstream Bio, Inc.
RESEARCH TOOLSreports
Want to see UPB full AI Analyst Report?

Upstream Bio, Inc. (UPB) Stock News & Sentiment

264 Followers
Upstream Bio Maintained at Buy as Verekitug’s Differentiated Efficacy Supports Steady $42 Price Target
Premium
Ratings
Upstream Bio Maintained at Buy as Verekitug’s Differentiated Efficacy Supports Steady $42 Price Target
3d ago
UPB
Yaron Werber Reiterates Buy Rating on Verekitug Developer, Citing Differentiated TSLP Profile, Streamlined Late‑Stage Path, and Cash Runway Through 2027
Premium
Ratings
Yaron Werber Reiterates Buy Rating on Verekitug Developer, Citing Differentiated TSLP Profile, Streamlined Late‑Stage Path, and Cash Runway Through 2027
9d ago
UPB
3 Best High-Risk, High-Reward Stocks to Buy Now, According to Analysts – 4/9/2026
Premium
Market News
3 Best High-Risk, High-Reward Stocks to Buy Now, According to Analysts – 4/9/2026
1M ago
UPB
AIOT
Validating the IL-13/TSLP Axis: Upstream Bio’s Verekitug Positioned for Differentiated Asthma Efficacy and Favorable Risk–Reward
Premium
Ratings
Validating the IL-13/TSLP Axis: Upstream Bio’s Verekitug Positioned for Differentiated Asthma Efficacy and Favorable Risk–Reward
1M ago
UPB
VALIANT Asthma Trial Update: What Upstream Bio’s Phase 2 Milestone Means for Investors
Premium
Company Announcements
VALIANT Asthma Trial Update: What Upstream Bio’s Phase 2 Milestone Means for Investors
2M ago
UPB
Upstream Bio Launches $150 Million At-The-Market Program
Premium
Company Announcements
Upstream Bio Launches $150 Million At-The-Market Program
2M ago
8K
UPB
Upstream Bio Initiated at Buy: Verekitug’s Quarterly Dosing Strategy Positions It for Potential Best-in-Class Efficacy vs. TSLP Competitors
Premium
Ratings
Upstream Bio Initiated at Buy: Verekitug’s Quarterly Dosing Strategy Positions It for Potential Best-in-Class Efficacy vs. TSLP Competitors
2M ago
UPB
More UPB News >

UPB News on the Web

LifeSci Capital Reaffirms Their Buy Rating on Upstream Bio, Inc. (UPB)
TipRanks News
Neutral
Upstream Bio price target lowered to $50 from $51 at Mizuho
TipRanks News
Neutral
Truist Financial Reaffirms Their Buy Rating on Upstream Bio, Inc. (UPB)
TipRanks News
Neutral
Yaron Werber Reiterates Buy Rating on Verekitug Developer, Citing Differentiated TSLP Profile, Streamlined Late‑Stage Path, and Cash Runway Through 2027
TipRanks News
Neutral
Analysts Offer Insights on Healthcare Companies: Icecure Medical (ICCM) and Upstream Bio, Inc. (UPB)
TipRanks News
Bullish
Analysts Have Conflicting Sentiments on These Healthcare Companies: Bolt Biotherapeutics (BOLT) and Upstream Bio, Inc. (UPB)
TipRanks News
Bullish
Upstream Bio reports Q1 revenue $1.03M, consensus $347,170
TipRanks News
Bullish
Upstream Bio to present new data from Phase 2 Vibrant trial of Verekitug
TipRanks News
Bullish

News Score - Last 7 Days

Very Positive
UPB
Sector Average
Media Buzz
This Week4 articles
Weekly Average1.5 articles
News Sentiment
This Week100%
Sector Average78%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is UPB’s Media Buzz Sentiment?
4 articles about UPB were published this week. In an average week, 1.5 articles are published.
    What is UPB’s weekly average amount of articles?
    In an average week, 1.5 articles about UPB are published.
      What is UPB’s News Sentiment?
      100% of articles about UPB were positive this week, compared to its sector average of 78%.
        Healthcare Stocks that are Trending in the News
        GOSSGossamer Bio
        RLAYRelay Therapeutics
        IMVTImmunovant
        ROIVRoivant Sciences
        ILAIsland Pharmaceuticals Ltd
        Showing the stocks with the most bullish news sentiment over the past week